Diabetic Nephropathy Market - Size, Trend, Analysis, Share to 2020

1. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) Persistence Market Research Diabetic Nephropathy Market is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020 - Persistence Market Research Persistence Market Research 1

2. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) Persistence Market Research Released New Market Report “Global Market Study on Diabetic Nephropathy Market – Asia to Witness Highest Growth by 2020,”.The global diabetic nephropathy market was valued at USD 2,262.2 million in 2014 and is expected to grow at a CAGR of 5.6% from 2014 to 2020, to reach an expected value of USD 3,145.9 million in 2020. Request Customize Full TOC: http://www.persistencemarketresearch.com/toc/3594 Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Globally, the diabetic nephropathy market is witnessing significant growth due to increasing prevalence of diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development and raising awareness about diabetes and kidney-related disorders are also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. In North America, various government programs are spreading awareness about diabetes and related renal complications. For instance, the National Kidney Disease Education Program, one of the major programs organized by the U.S. government, for increasing awareness about the various kidney diseases. In addition, the number of diabetic patients are also increasing in the region; according to the SciELO Public Health, approximately 35 million people were affected with diabetes mellitus in 2000 and this number is expected to reach 64 million by 2025 in North America. In Europe, rise in healthcare expenditure for diabetes treatment and increasing prevalence of diabetes in the various part of Europe is boosting the growth of the European diabetic nephropathy market. According to IDF, approximately 55.4 million people had diabetes in Persistence Market Research 2

3. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) 2010 and the number is expected to reach 66.5 million by 2030 in Europe. According to the IDF, healthcare expenditure for diabetes treatment was approximately USD 105.5 billion in 2010 and is expected to reach USD 124.6 billion by 2030 in Europe. Asia represents the fastest growing region in the diabetic nephropathy market due to the rise in a diabetic population in various countries such as Japan and the Southeast Asian countries. According to the International Diabetes Federation (IDF), developing countries, such as India and China, are expected to have the highest number of diabetes mellitus patients compared to developed countries, such as the U.S. and Germany. Request Sample Report: http://www.persistencemarketresearch.com/samples/3594 Sanofi is one of the leading players in the diabetic nephropathy market. Other major players in diabetic nephropathy market include Eli Lilly and Company, Mitsubishi Tanabe Pharma Corporation, Novartis AG, Pfizer, Inc., Abbott Laboratories, AbbVie, Inc., Bayer AG, Merck & Co., Inc., Bayer AG and Reata Pharmaceuticals, Inc. Buy Full Report: http://www.persistencemarketresearch.com/market-research/diabetic- nephropathy-market.asp The global diabetic nephropathy market is segmented as follows: Diabetic nephropathy market, by model of treatment Disease Modifying Therapies Angiotensin-Converting Enzyme Inhibitors • Angiotensin Receptor Blockers • Diuretics • Calcium Channel Blockers • Persistence Market Research 3

4. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) Renin Inhibitors • Connective Tissue Growth Factor Inhibitors • Antioxidant Inflammation Modulator • Monocyte Chemoattractant Proteins Inhibitor • Endothelin-A Receptor Antagonist • G Protein-Coupled Receptors • Diabetic nephropathy market, by geography North America U.S. • Canada • Europe Germany • France • U.K. • Asia Japan • China • India • Rest of the World (RoW) Market History: Diabetic nephropathy is a disease of the kidney glomerulus and one of the most significant complications in terms of mortality and morbidity for patients with diabetes. Diabetic nephropathy is mainly characterized by macroalbuminuria. The presence of over 300 milligrams of albumin in the urine in 1 day is known as macroalbuminuria. Globally, the diabetic nephropathy market is witnessing significant growth due to rise in the incidence of Persistence Market Research 4

5. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) diabetes and obesity in different regions of the world. In addition, increasing R&D investments in drug discovery and development by various companies, such as Sanofi, Eli Lilly and Mitsubishi Tanabe Pharma is also driving the growth of the market. However, stringent regulatory requirements and longer approval time for drugs as well as the lack of comprehensive therapeutic management for diabetic nephropathy are inhibiting the growth of diabetic nephropathy market. The global diabetic nephropathy market is estimated at USD 2,262.2 million in 2014. It is likely to grow at a CAGR of 5.6% from 2014 to 2020 to reach USD 3,145.9 million in 2020. North America has the largest market for the global diabetic nephropathy market. However, In terms of growth, Asia is the fastest growing region. Disease Modifying Therapies (DMT) is the largest and fastest growing mode of treatment, whereas ACE inhibitors, is the largest and fastest growing DMT of diabetic nephropathy. North American market is estimated at USD 931.0 million in 2014 and is expected to reach USD 1,302.0 million in 2020, growing at a CAGR of 5.7% from 2014 to 2020. The global DMT market is estimated at USD 2,093.5 million in 2014 and is expected to reach USD 2,929.8 million in 2020, growing at a CAGR of 5.8% from 2014 to 2020. Persistence Market Research 5

6. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) Table of Content Chapter 1 Preface 1.1 Report Description 1.2 Research Methodology 1.3 Assumptions Chapter 2 Market Synopsis Chapter 3 Porter’s Five Forces Analysis 3.1 Bargaining Power of Suppliers 3.2 Bargaining Power of Buyers 3.3 Threat of New Entrants 3.4 Threat of Substitutes 3.5 Intensity of Rivalry Chapter 4 Industry Overview 4.1 Market Definition 4.2 Market Drivers 4.2.1 Increasing prevalence of diabetes 4.2.2 Globally rising obesity increasing the prevalence of diabetes 4.2.3 Increasing R&D investments in drug discovery and development 4.2.4 Rising awareness among people about diabetes and kidney-related disorders 4.3 Impact Analysis of Market Drivers 4.4 Market Restraints 4.4.1 Strict regulatory requirements and long approval time for drugs 4.4.2 Lack of comprehensive therapeutic management for diabetic nephropathy 4.5 Impact Analysis of Market Restraints 4.6 Market Trends 4.6.1 Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market Chapter 5 Global Market Size and Forecast Persistence Market Research 6

7. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) Chapter 6 Market Size and Forecast by Mode of Treatment 6.1 Disease Modifying Therapies 6.1.1 Angiotensin-Converting Enzyme Inhibitors 6.1.2 Angiotensin Receptor Blockers 6.1.3 Diuretics 6.1.4 Calcium Channel Blockers 6.1.5 Renin Inhibitors 6.1.6 Connective Tissue Growth Factor Inhibitors 6.1.7 Antioxidant Inflammation Modulator 6.1.8 Monocyte Chemoattractant Proteins Inhibitor 6.1.9 Endothelin-A Receptor Antagonist 6.1.10 G Protein-Coupled Receptors Chapter 7 Market Size and Forecast by Geography 7.1 North America 7.1.1 Scenario in the U.S. 7.1.2 Scenario in Canada 7.2 Europe 7.2.1 Scenario in Germany 7.2.2 Scenario in France 7.2.3 Scenario in the U.K. 7.3 Asia 7.3.1 Scenario in Japan 7.3.2 Scenario in China 7.3.3 Scenario in India Chapter 8 Pipeline Drugs for Diabetic Nephropathy 8.1 Drugs Under Development for Diabetic Nephropathy Chapter 9 Competitive Scenario 9.1 Competitive Benchmarking Chapter 10 Company Profiles 10.1 Novartis AG 10.1.1 Company overview Persistence Market Research 7

8. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) 10.1.2 Products and services 10.1.3 Financial performance 10.1.4 Key developments 10.2 Merck & Co., Inc. 10.2.1 Company overview 10.2.2 Products and services 10.2.3 Financial performance 10.2.4 Key developments 10.3 Pfizer, Inc. 10.3.1 Company overview 10.3.2 Products and services 10.3.3 Financial performance 10.3.4 Key developments 10.4 Abbott Laboratories 10.4.1 Company overview 10.4.2 Products and services 10.4.3 Financial performance 10.4.4 Key developments 10.5 Sanofi 10.5.1 Company overview 10.5.2 Products and services 10.5.3 Financial performance 10.5.4 Key developments 10.6 Eli Lilly and Company 10.6.1 Company overview 10.6.2 Products and segments 10.6.3 Financial performance 10.6.4 Key developments 10.7 Reata Pharmaceuticals, Inc. 10.7.1 Company overview 10.7.2 Products and segments 10.7.3 Financial performance 10.7.4 Key developments 10.8 Bayer AG 10.8.1 Company overview Persistence Market Research 8

9. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) 10.8.2 Products and segments 10.8.3 Financial performance 10.8.4 Key developments 10.9 AbbVie, Inc. 10.9.1 Company overview 10.9.2 Products and segments 10.9.3 Financial performance 10.9.4 Key developments 10.10 Mitsubishi Tanabe Pharma Corporation 10.10.1 Company overview 10.10.2 Products and segments 10.10.3 Financial performance 10.10.4 Key developments List of Tables TABLE 1 Market Snapshot: Diabetic nephropathy market, 2014 and 2020 TABLE 2 Drivers for diabetic nephropathy market: Impact analysis TABLE 3 Estimated average timelines for clinical trial approval in various countries TABLE 4 Restraints for diabetic nephropathy market: Impact analysis TABLE 5 Global diabetic nephropathy market size, by region, 2010 – 2013 (USD thousand) TABLE 6 Global diabetic nephropathy market size, by region, 2014 – 2020 (USD thousand) TABLE 7 Global diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 8 Global diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 9 Global DMT market size, by region, 2010 – 2013 (USD thousand) TABLE 10 Global DMT market size, by region, 2014 – 2020 (USD thousand) TABLE 11 Global DMT market size, by drug categories, 2010 – 2013 (USD thousand) TABLE 12 Global DMT market size, by drug categories, 2014 – 2020 (USD thousand) TABLE 13 Global ACE inhibitors market size, by region, 2010 – 2013 (USD thousand) TABLE 14 Global ACE inhibitors market size, by region, 2014 – 2020 (USD thousand) TABLE 15 Global ARBs market size, by region, 2010 – 2013 (USD thousand) TABLE 16 Global ARBs market size, by region, 2014 – 2020 (USD thousand) TABLE 17 Global diuretics market size, by region, 2010 – 2013 (USD thousand) Persistence Market Research 9

10. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) TABLE 18 Global diuretics market size, by region, 2014 – 2020 (USD thousand) TABLE 19 Global CCBs market size, by region, 2010 – 2013 (USD thousand) TABLE 20 Global CCBs market size, by region, 2014 – 2020 (USD thousand) TABLE 21 Global renin inhibitors market size, by region, 2010 – 2013 (USD thousand) TABLE 22 Global renin inhibitors market size, by region, 2014 – 2020 (USD thousand) TABLE 23 Global CTGF inhibitors market size, by region, 2010 – 2013 (USD thousand) TABLE 24 Global CTGF inhibitors market size, by region, 2014 – 2020 (USD thousand) TABLE 25 Global AIM market size, by region, 2010 – 2013 (USD thousand) TABLE 26 Global AIM market size, by region, 2014 – 2020 (USD thousand) TABLE 27 Global MCP inhibitors market size, by region, 2010 – 2013 (USD thousand) TABLE 28 Global MCP inhibitors market size, by region, 2014 – 2020 (USD thousand) TABLE 29 Global ETAR market size, by region, 2010 – 2013 (USD thousand) TABLE 30 Global ETAR market size, by region, 2014 – 2020 (USD thousand) TABLE 31 Global GPCRs market size, by region, 2010 – 2013 (USD thousand) TABLE 32 Global GPCRs market size, by region, 2014 – 2020 (USD thousand) TABLE 33 The North American diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand) TABLE 34 The North American diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand) TABLE 35 The U.S. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 36 The U.S. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 37 The Canadian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 38 The Canadian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 39 The European diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand) TABLE 40 The European diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand) TABLE 41 The German diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 42 The German diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) Persistence Market Research 10

11. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) TABLE 43 The French diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 44 The French diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 45 The U.K. diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 46 The U.K. diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 47 The Asian diabetic nephropathy market size, by country, 2010 – 2013 (USD thousand) TABLE 48 The Asian diabetic nephropathy market size, by country, 2014 – 2020 (USD thousand) TABLE 49 The Japanese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 50 The Japanese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 51 The Chinese diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 52 The Chinese diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 53 The Indian diabetic nephropathy market size, by mode of treatment, 2010 – 2013 (USD thousand) TABLE 54 The Indian diabetic nephropathy market size, by mode of treatment, 2014 – 2020 (USD thousand) TABLE 55 Major pipeline drugs for diabetic nephropathy TABLE 56 Product categories of Novartis AG TABLE 57 Product categories of Merck & Co., Inc. TABLE 58 Product categories of Pfizer, Inc. TABLE 59 Product categories of Abbott Laboratories TABLE 60 Product categories of Sanofi TABLE 61 Product segments of Eli Lilly and Company TABLE 62 Product categories of Reata Pharmaceuticals, Inc. TABLE 63 Product categories of Bayer AG TABLE 64 Product categories of AbbVie, Inc. TABLE 65 Product categories of Mitsubishi Tanabe Pharma Corporation Persistence Market Research 11

12. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) List of Figures FIG. 1 Diabetic nephropathy market: Porter’s five forces analysis FIG. 2 Major DMT for diabetic nephropathy FIG. 3 Number of people with diabetes mellitus (20 – 79 years) in major countries, 2010, and 2030 (million) FIG. 4 Prevalence of overweight and obese males aged 30 years and above, 2005 and 2015 (%) FIG. 5 Prevalence of overweight and obese females aged 30 years and above, 2005 and 2015 (%) FIG. 6 Global diabetic nephropathy market share, by region, by value, 2013 FIG. 7 Global diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 8 Global DMT market share, by region, by value, 2013 30 FIG. 9 Global DMT market share, by disease categories, by value, 2013 FIG. 10 Global ACE inhibitors market share, by region, by value, 2013 FIG. 11 Global ARBs market share, by region, by value, 2013 FIG. 12 Global diuretics market share, by region, by value, 2013 FIG. 13 Global CCBs market share, by region, by value, 2013 FIG. 14 Global renin inhibitors market share, by region, by value, 2013 FIG. 15 Global CTGF inhibitors market share, by region, by value, 2013 FIG. 16 Global AIM market share, by region, by value, 2013 FIG. 17 Global MCP inhibitors market share, by region, by value, 2013 FIG. 18 Global ETAR market share, by region, by value, 2013 FIG. 19 Global GPCRs market share, by region, by value, 2013 FIG. 20 The North American diabetic nephropathy market share, by country, by value, 2013 FIG. 21 The U.S. diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 22 The Canadian diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 23 The European diabetic nephropathy market share, by country, by value, 2013 FIG. 24 The German diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 25 The French diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 26 The U.K. diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 27 The Asian diabetic nephropathy market share, by country, by value, 2013 Persistence Market Research 12

13. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) FIG. 28 The Japanese diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 29 The Chinese diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 30 The Indian diabetic nephropathy market share, by mode of treatment, by value, 2013 FIG. 31 Competitive landscape of diabetic nephropathy market, 2013 FIG. 32 Novartis AG’s net sales and net income, 2011 – 2013 (USD million) FIG. 33 Merck & Co., Inc.’s sales and net income, 2011 – 2013 (USD million) FIG. 34 Pfizer, Inc.’s revenue and net income, 2011 – 2013 (USD million) FIG. 35 Abbott Laboratories’ net sales and net earnings, 2011 – 2013 (USD million) FIG. 36 Sanofi’s net sales and net income, 2011 – 2013 (USD million) FIG. 37 Eli Lilly and Company’s revenue and net income, 2011 – 2013 (USD million) FIG. 38 Bayer AG’s net sales and net income, 2011 – 2013 (USD million) FIG. 39 AbbVie, Inc.’s net sales and net earnings, 2011 – 2013 (USD million) FIG. 40 Mitsubishi Tanabe Pharma Corporation’s net sales and net earnings, 2011 – 2013 (USD million) About Us: Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs. PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values. Persistence Market Research 13

14. Diabetic Nephropathy Market - North America has the largest market, followed by Europe (2020) Contact Us: Persistence Market Research 305 Broadway 7th Floor, New York City, NY 10007, United States, USA - Canada Toll Free: 800-961-0353 Email: sales@persistencemarketresearch.com Web: http://www.persistencemarketresearch.com Persistence Market Research 14